Understand the source comparison
Sleep Peptides 2026 Update: Clinical Trial Comparison
DSIP GABA-A receptor agonism in VLPO Strong (Phase 2/3 trials, polysomnography validation) 90 minutes pre-sleep, subcutaneous Minimal. Transient injection site redness Most clinically validated for extending slow-wave sleep; timing-dependent efficacy Epithalam
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP
- GABA-A receptor agonism in VLPO
- Strong (Phase 2/3 trials, polysomnography validation)
- 90 minutes pre-sleep, subcutaneous
- Minimal. Transient injection site redness
- Most clinically validated for extending slow-wave sleep; timing-dependent efficacy
- Epithalamin
- Pineal AANAT upregulation, melatonin restoration
- Moderate (Phase 2 trials, primarily Eastern European research)
- Nightly for 10–14 days minimum
- None reported in trials under 20-day protocols
- Best for age-related circadian disruption; requires multi-week commitment
- Selank
- Anxiolytic via GABAergic modulation, cortisol rhythm stabilisation
- Moderate (Phase 2 trials, subjective sleep quality metrics)
- 300mcg intranasal, twice daily (morning and evening)
- Rare. Mild nasal irritation
- Targets anxiety-driven insomnia; indirect sleep benefit through reduced hyperarousal
- MK-677
- Ghrelin receptor agonism, GH secretion
- Weak for sleep (strong for GH elevation)
- 25mg daily, evening
- Daytime somnolence (34% of users), increased appetite
- Increases REM but impairs daytime function; poor risk-benefit for sleep alone
- Thymalin
- Proposed immune modulation (mechanism unclear for sleep)
- None (no polysomnography changes in controlled trials)
- N/A
- None specific to sleep protocols
- Lacks plausible neurological pathway; anecdotal claims not replicated in trials